HighTower Advisors
BIIB icon

HighTower Advisors’s Biogen BIIB Stock Holding History

HighTower Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$1K – 2611
2020
Q3 		$1K Hold
100
– – ﹤0.01% 2518
2020
Q2 		$2K Buy
+100
New +$30.1K ﹤0.01% 2377

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighTower Advisors's BIIB Position: Q1 2026 in Review

HighTower Advisors increased its Biogen (BIIB) stake by 317% in Q1 2026, buying an estimated $6.98M and bringing the position to 49,851 shares worth $9.14M. The position accounts for 0.01% of the portfolio, ranked #925.

HighTower Advisors first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $11.7M in Q3 2018. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • HighTower Advisors held 49,851 shares of Biogen worth $9.14M as of Q1 2026.
  • HighTower Advisors bought 37,892 Biogen shares in Q1 2026, an estimated $6.98M.
  • Biogen made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #925 holding.
  • HighTower Advisors first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
  • HighTower Advisors's Biogen position peaked at $11.7M in Q3 2018.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.